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of this report, the term ‘Member States’ shall include the United Kingdom. 
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4en-PINACA is a synthetic cannabinoid receptor agonist. Similar to other synthetic 
cannabinoids, it is sold as a ‘legal’ replacement for cannabis and controlled synthetic 
cannabinoids. Because of their high potency, synthetic cannabinoids can pose a high risk of 
severe poisoning, which in some cases can be fatal.  
In Europe, MDMB-4en-PINACA is monitored by the EMCDDA as a new psychoactive 
substance (1) through the European Union Early Warning System (EWS) in accordance with 
Article 5a of Regulation (EC) No 1920/2006 (as amended) (2,3). 
MDMB-4en-PINACA was formally notified as a new psychoactive substance (4,5) by the 
EMCDDA on behalf of Slovenia on 23 August 2018. The notification related to a collected 
sample (test purchase) of 7.89 g of yellow powder. However, based on information 
subsequently reported to the EMCDDA by Germany concerning a seizure made by Police, 
MDMB-4en-PINACA has been available on the European drug market since at least 2017. 
Since the formal notification, information on MDMB-4en-PINACA has been exchanged 
between the EMCDDA and the European Union EWS Network (EMCDDA, Europol, Reitox 
national focal points, and the Commission); the EMA have been kept duly informed. 
On 10 July 2020, the EMCDDA issued a public health advisory to the Network highlighting 
an increase in the number of identifications of MDMB-4en-PINACA in Europe and the 
potential risks posed by this.  
On 27 July 2020, the EMCDDA informed the EWS Network that based on potential public 
health risks, the EMCDDA had added MDMB-4en-PINACA to the list of new psychoactive 
substances under intensive monitoring (6) and requested that the Network expedite reporting 
of any event involving MDMB-4en-PINACA to the EMCDDA until further notice. 
Article 5b of Regulation (EC) No 1920/2006 (as amended) requires that ‘Where the Centre, 
the Commission or a majority of the Member States considers that information shared on a 
new psychoactive substance collected pursuant to Article 5a in one or more Member States 
 
1 As defined in point 4 of Article 1 of Council Framework Decision 2004/757/JHA of 25 October 2004 laying down minimum 
provisions on the constituent elements of criminal acts and penalties in the field of illicit drug trafficking (OJ L 335, 11.11.2004, 
p. 8). 
2 Regulation (EC) No 1920/2006 of the European Parliament and of the Council of 12 December 2006 on the European 
Monitoring Centre for Drugs and Drug Addiction (recast) (O J L 376, 27.12.2006, p.1-13). 
3 Regulation (EU) 2017/2101 of the European Parliament and of the Council of 15 November 2017 amending Regulation (EC) 
No 1920/2006 as regards information exchange on, and an early warning system and risk assessment procedure for, new 
psychoactive substances (O J L 305, 21.11.2017, p.1-7). 
4 EMCDDA (2019), EMCDDA operating guidelines for the European Union Early Warning System on new psychoactive 
substances, European Monitoring Centre for Drugs and Drug Addiction, Publications Office of the European Union, 
Luxembourg. https://www.emcdda.europa.eu/publications/guidelines/operating-guidelines-for-the-european-union-early-
warning-system-on-new-psychoactive-substances_en  
5 EMCDDA (2019), EMCDDA operating guidelines for the European Union Early Warning System on new psychoactive 
substances, Guidance note 2. Formal notification of a new psychoactive substance. 
https://www.emcdda.europa.eu/system/files/publications/12213/downloads/Guidance%20Note%202-
%20Formal%20notification%20of%20a%20new%20psychoactive%20substance.pdf  
6 EMCDDA (2019), EMCDDA operating guidelines for the European Union Early Warning System on new psychoactive 




gives rise to concerns that the new psychoactive substance may pose health or social risks 
at Union level, the Centre shall draw up an initial report on the new psychoactive substance’.  
The initial report is submitted to the Commission and the Member States. The purpose of the 
initial report is to provide scientific evidence to the Commission to allow it to make an 
informed decision regarding whether or not there is a need to request a risk assessment on 
a new psychoactive substance as set out in Article 5c of Regulation (EC) No 1920/2006 (as 
amended). 
Based on the information reported by the Network, on 2 September 2020, the EMCDDA 
assessed the existing information (7,8) on MDMB-4en-PINACA, based on the following 
criteria:  
• reports of health problems; 
• reports of social problems; 
• reports of seized material; 
• pharmacological and toxicological properties and analogy with better-studied 
substances; and, 
• potential for further spread.  
The EMCDDA concluded that the assessment gave rise to concerns that MDMB-4en-
PINACA may pose health or social risks at Union level, and, consequently, determined that 
an initial report should be produced. 
2. Information collection process 
In accordance with the requirements of Article 5b of the Regulation, on 9 September 2020, 
the EMCDDA launched a procedure for the collection of additional information on MDMB-
4en-PINACA in order to support the production of the initial report.  
The EMCDDA collected information through: 
• a structured reporting form to the Reitox national focal points in the Member States, 
Turkey, and Norway (Article 5b(4)); 
• routine monitoring of open source information;  
• a search of open source information conducted specifically for the production of the 
initial report which included: scientific and medical literature, official reports, grey 
literature, internet drug discussion forums and related websites (hereafter, ‘user 
websites’), and online vendors. 
 
7 EMCDDA (2019), EMCDDA operating guidelines for the European Union Early Warning System on new psychoactive 
substances, European Monitoring Centre for Drugs and Drug Addiction, Publications Office of the European Union, 
Luxembourg. https://www.emcdda.europa.eu/publications/guidelines/operating-guidelines-for-the-european-union-early-
warning-system-on-new-psychoactive-substances_en  
8 This included information reported to the EMCDDA through the Early Warning System, including case reports and aggregated 
datasets. 
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In addition, the EMCDDA also submitted requests to: 
• The World Health Organization (WHO) in order to determine if MDMB-4en-PINACA 
is under assessment or has been under assessment within the system established 
by the 1961 Single Convention on Narcotic Drugs, as amended by the 1972 
Protocol, and the 1971 Convention on Psychotropic Substances (‘United Nations 
system’). 
• The European Medicines Agency (EMA) in order to determine if MDMB-4en-PINACA 
is used as an active substance in a medicinal product for human or veterinary use at 
Union or national level (Article 5b(5)). Specifically, the EMA was asked if MDMB-4en-
PINACA is an active substance in: 
a. a medicinal product for human use or in a veterinary medicinal product that 
has obtained a marketing authorisation in accordance with Directive 2001/83/ 
EC of the European Parliament and of the Council (9), Directive 2001/82/EC 
of the European Parliament and of the Council (10) or Regulation (EC) No 
726/2004 of the European Parliament and of the Council (11);  
b. a medicinal product for human use or in a veterinary medicinal product that is 
the subject of an application for a marketing authorisation;  
c. a medicinal product for human use or in a veterinary medicinal product whose 
marketing authorisation has been suspended by the competent authority;  
d. an unauthorised medicinal product for human use in accordance with Article 5 
of Directive 2001/83/EC or in a veterinary medicinal product prepared 
extemporaneously by a person authorised to do so under national law in 
accordance with point (c) of Article 10(1) of Directive 2001/82/EC;  
e. an investigational medicinal product as defined in point (d) of Article 2 of 
Directive 2001/20/EC of the European Parliament and of the Council (12). 
• Europol in order to provide information on the involvement of criminal groups in the 
manufacture, distribution and distribution methods, and trafficking of MDMB-4en-
PINACA, and in any use of MDMB-4en-PINACA (Article 5b(6)).  
• The European Chemicals Agency (ECHA), the European Centre for Disease 
Prevention and Control (ECDC) and the European Food Safety Authority (EFSA) in 
 
9 Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to 
medicinal products for human use (OJ L 311, 28.11.2001, p. 67). 
10 Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to 
veterinary medicinal products (OJ L 311, 28.11.2001, p. 1). 
11 Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community 
procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a 
European Medicines Agency (OJ L 136, 30.4.2004, p. 1). 
12 Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, 
regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the 
conduct of clinical trials on medicinal products for human use (OJ L 121, 1.5.2001, p. 34). 
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order to provide the information and data at their disposal on MDMB-4en-PINACA 
(Article 5b(7)). 
The information collection process was concluded on 7 October 2020. The EMCDDA 
received responses from all 28 Member States, Turkey, and Norway. In addition, the 
EMCDDA received responses from WHO, EMA, Europol, ECHA, ECDC, and EFSA. 
3. Information required by Article 5b(2) of the Regulation 
The order and titles of subsections 3.1 to 3.9, below, are as they appear in Article 5b(2) of 
Regulation (EC) No 1920/2006 (as amended); sections 3.1 to 3.4 are cross-referenced with 
the headings of Article 5b(2a) to Article 5b(2d) of the Regulation. 
3.1. Nature, number and scale of incidents showing health and social problems in 
which the new psychoactive substance may potentially be involved, and the 
patterns of use of the new psychoactive substance  
Detections of MDMB-4en-PINACA may be under-reported since the substance may not 
been routinely screened for in forensic and toxicology laboratories. Therefore, the presence 
of MDMB-4en-PINACA on the European drug market may be undetected in some areas, 
including in law enforcement seizures as well as in biological samples related to serious 
adverse events. It is also important to note, that, due to differences in reporting practices 
across Europe, identifications of MDMB-4en-PINACA may be unreported to the Reitox 
national focal points and as a consequence to the EMCDDA.  
3.1.1. Information from seizures, collected and biological samples 
As of 8 October 2020, MDMB-4en-PINACA has been identified in 850 detections across 20 
Member States, Turkey, and Norway. These relate to 768 seizures, 13 collected samples 
and 69 biological samples. In addition, three detections were reported by Slovenia (13) after 
the data submission deadline, which have not been included in the dataset. 
Information from seizures  
In total, 768 seizures of MDMB-4en-PINACA, amounting to over 63 kg, were reported to the 
EMCDDA by 20 Member States and Norway, as follows: the United Kingdom (380 seizures), 
Hungary (223), Germany (40), France (35), Sweden (20), Belgium (12), Poland (11), 
Bulgaria (10), Latvia (7), Lithuania (7), Slovakia (5), Slovenia (4), Spain (3), Austria (2), 
Cyprus (2), Romania (2), Croatia (1), Greece (1), the Netherlands (1), Portugal (1), and 
Norway (1). In addition, Turkey reported 663 additional cases that may contain duplicates 
and have not been included in the count. 
The majority of the seizures comprise police cases (730), with 108 (15%) of the seizures 
taking place in prisons and other custodial settings. There were 38 customs cases reported. 
 
13 Slovenia reported three seizures of herbal material made by the police in prison, which contained also 4F-MDMB-BICA (3), 
5F-MDMB-PICA (3), 5F-EMB-PICA (3), Cumyl-PeGaClone (1), Cumyl-5F-PINACA (1), MDMB-PINACA (1), 4F-MDMB-BICA 
(1) and traces of JWH-210 (1). 
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Seizures included smoking mixtures, powders, liquids, blotters and unspecified physical 
forms. A summary is provided below.  
Customs seizures 
A total of 38 customs seizures of MDMB-4en-PINACA were reported by France (13), 
Belgium (12), Poland (4), Germany (3), Sweden (2), Bulgaria (1), Lithuania (1), the 
Netherlands (1), and Norway (1). When reported, the seizures occurred between May 2019 
and September 2020. In the majority of cases (36) no other substances were reported as 
identified in the seizures. 
MDMB-4en-PINACA was detected in powders, and smoking mixtures. A summary is 
provided below.  
- Powders 
In total, 22 customs seizures, amounting to 44.5 kg were in powder form. Overall, most of 
the quantities seized by customs were made in 2020 (44.36 kg; 99.7%), while only 115 
grams were seized in 2019.  
In total, Belgian customs reported 11 seizures of MDMB-4en-PINACA amounting to 44.3 kg 
of powder. These included two single seizures amounting to 16 kg each. All the seizures 
reported by Belgium originated in China and the destinations were reported as: Turkey (for 
each of the 16 kg seizures); the United Kingdom (for 3 seizures amounting to 7.2 kg); Israel 
(2, 2.7 kg); Reunion (France) (1, 500 grams); Netherlands (1, 1.5 kg); Belgium (1, 300 
grams); and Romania (1, 100 grams). No other substances were reported as identified in 
any of the seizures. 
Lithuanian customs reported a seizure of shipment from Spain of MDMB-4en-PINACA in a 
package labelled ‘5CL’. 
- Smoking mixtures 
Four of the seizures, amounting to 287 grams, were in herbal form. In 2 of them 5F-MDMB-
PICA was also detected. 
- Other 
The physical form for 12 of the seizures was reported as an ‘other’ or not specified and 
amounts to approximately 2.5 kg. 
Police seizures 
A total of 730 seizures made by police were reported by 18 Member States, as follows: the 
United Kingdom (380 seizures), Hungary (223), Germany (37), France (22), Sweden (18), 
Bulgaria (9), Latvia (7), Poland (7), Lithuania (6), Slovakia (5), Slovenia (4), Spain (3), 
Austria (2), Cyprus (2), Romania (2), Croatia (1), Greece (1), and Portugal (1).  
Seizures occurred between 2017 and September 2020. Where known, seizures occurred in 
2017 (1), 2018 (14), 2019 (325), and 2020 (388). The police seizures amounted to 
approximately 15.9 kg. In terms of quantity, material containing MDMB-4en-PINACA was 
seized mainly in 2020 (9.7 kg) and 2019 (6.2 kg). 
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Out of the 730 police seizures, 108 seizures occurred in prisons, including correction houses 
and were reported by: the United Kingdom (98), Slovenia (4), Lithuania (3), Cyprus (1), 
France (1) and Germany (1). The seizures occurred between June 2019 and July 2020. In 
100 cases, the seizures were in blotter form, including all cases reported by the United 
Kingdom, and amounted to 135 blotters. In 4 seizures, reported by Slovenia, MDMB-4en-
PINACA was detected in herbal material amounting to 5.2 grams. Other synthetic 
cannabinoids were detected in 10 of the seizures; these included: 5F-MDMB-PICA (8), 4F-
MDMB-BICA (3), and 4F-MDMB-BINACA (3). In the case reported by Cyprus, 14 
impregnated sheets of A4 sized paper which had been concealed inside a television were 
seized in a delivery of a package to a prison. 
The remaining 622 seizures reported by the police were detected in smoking mixtures, 
powders, blotters, and liquids. A summary is provided below. 
- Smoking mixtures 
A total of 301 seizures of smoking mixtures amounting to 4.5 kg were reported by: Hungary 
(194), the United Kingdom (49), Germany (32), Latvia (7), Sweden (7), Slovakia (5), Poland 
(3), Lithuania (2), Greece (1), and Croatia (1). Seizures occurred between 2017 and 
September 2020. In 67 cases, other synthetic cannabinoids were detected: mainly 5F-
MDMB-PICA (39), 4F-MDMB-BICA (11), and 4F-MDMB-BINACA (11). In 3 cases reported 
by the United Kingdom, cannabis and THC were detected. In 4 cases reported by the United 
Kingdom, nicotine was detected. Seizures ranged from 0.03 grams to 842 grams, being 
most of the seizures (260) under 10 grams. Germany reported MDMB-4en-PINACA in 
branded ‘legal-high’ type products: ‘Pico Bello Extra Strong’ (seized in 2017, containing 5-
ADB and 5-ADB-PINACA), ‘Pico Bello Made In Holland’ (3 seizures, containing also 5F-
MDMB-PICA). Mixtures were also found in joints, in small non-branded grip-seal clear bags 
and inside paper wrappers. 
- Powders 
In total, 45 seizures of powder amounting to 2.6 kg were reported by: Hungary (17), Sweden 
(11), the United Kingdom (5), Germany (3), Spain (3), Poland (2), Cyprus (1), Lithuania (1), 
Portugal (1), and Romania (1). Seizures ranged from 0.01 grams to approximately 1 kg, 
being most of the seizures (28) under 10 grams. Only three seizures were reported to 
contain other substances: 2.7% of dimethylsulphone (1); 4F-MDMB-BINACA (1), and 5F-
MDMB-2201 (1). 
- Blotters 
A total of 41 seizures amounting to 150 blotters were reported by 3 Member States: the 
United Kingdom (30), Hungary (11), and Germany (1). In 11 cases, other synthetic 
cannabinoids were also detected, 5F-MDMB-PICA (9 cases), 4F-MDMB-BINACA (2) and 
AMB-FUBINACA (1). 
- Liquids 
In total, 15 seizures of liquid amounting to 39 ml were reported by 3 Member States: France 
(11), the United Kingdom (3) and Hungary (1). Of these, in 11 seizures other psychoactive 
substances were detected including mainly synthetic cannabinoids. The liquids were found 
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in most cases in a vial, as e-liquids for vaping (10 cases), and in one case in an e-cigarette 
with a half empty cartridge. 
- Other 
For 219 seizures amounting to close to 8.8 kg the physical form was not specified, reported 
as ‘other’ or unknown. These included 5 single seizures amounting to close to 1 kg each, 
reported by the United Kingdom, which occurred in February 2020. 
Information from collected samples 
A total of 13 collected samples were reported by 5 Member States: France (5 samples), 
Poland (3), Germany (2), Slovenia (2) and Belgium (1). Of these, 7 samples were in powder 
form, 4 samples were in liquid form and for the remaining 2 samples the form was reported 
as ‘other’. 
Powders were collected as beige or yellow solids. In one case reported by Slovenia MDMB-
4en-PINACA was purchased from an internet website as ‘5-CL-ADB-A’ for the price of 21 
dollars per gram. 
All the cases where MDMB-4en-PINACA was detected in liquid form, which were reported 
by France (3) and Belgium (1), were recovered from poisoning cases.  
The 3 liquid samples reported by France were collected between September 2019 and 
January 2020 and were collected from patients with acute non-fatal poisonings. One of the 
three samples, sold under the street name ‘PTC’ (from the French, ‘pète ton crane’), was 
related to poisonings with probable exposure to MDMB-4en-PINACA of two males, aged 16. 
In the remaining 2 samples of liquid, 4F-MDMB-BINACA was also detected. One of the e-
liquids, labelled ‘Born to DIY’, was sold among school students.  
The sample reported by Belgium, was in an e-liquid for vaping found on an poisoned patient. 
The sample also contained 4F-MDMB-BINACA, 5Cl-AKB48, 4-cyano-CUMYL-BUTINICA, 
5F-MDMB-PICA, 5F-CUMYL-PINACA and benzylone in lower concentrations than 4F-
MDMB-BINACA. The case occurred in July 2020. 
Two additional samples reported by France, which also contained 5F-MDMB-PICA, were 
collected in the overseas department and region of Mayotte and sold as ‘Chimique’. 
Information from biological samples 
Serious adverse events with confirmed exposure to MDMB-4en-PINACA from biological 
samples (11 acute intoxications reported by the United Kingdom, and 4 deaths reported by 
United Kingdom (3) and Sweden (1)) are discussed in section 3.1.2.  
In addition to these, 54 detections of MDMB-4en-PINACA in biological samples were 
reported by Turkey (36) and Hungary (18)14. Detections included: 
- 3 samples associated with non-fatal intoxications, reported by Hungary; 
 
14 In addition, Turkey reported 101 samples associated with non-fatal intoxications which may contain duplicates and therefore 
have not been included in the total count.  
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- 4 cases of persons suspected of driving under the influence of drugs (including two 
traffic accidents), reported by Hungary; 
- 11 cases of drug consumption, reported by Hungary; 
- 36 samples taken by the law enforcement agencies, reported by Turkey. 
3.1.2. Health problems 
Acute poisonings 
A total of 11 acute non-fatal poisonings with confirmed exposure to MDMB-4en-PINACA 
were reported by the United Kingdom (15). The cases occurred during 2020. Of the cases, 
nine were male and two were female. The males were aged between 19 and 60 (mean 36; 
median 32.5).The females were aged 31 and 35. 
All the cases included clinical features of poisoning similar to those reported for synthetic 
cannabinoids. In all cases other substances were identified. 
In ten of the cases, the poisoning was considered life-threatening and required 
hospitalisation of the patient. 
Deaths 
A total of 4 deaths with confirmed exposure to MDMB-4en-PINACA were reported by the 
United Kingdom (3) and Sweden (1). The cases occurred between 2019 and 2020. 
Of the deaths, two were male and two were female. The males were aged 37 and 41; the 
females were aged 31.  
In all cases, other substances were identified, including central nervous system depressants 
(such as alcohol, opioids, synthetic cannabinoids and benzodiazepines). In 2 cases, 
metabolites of fluoro-MDMB-PICA metabolites were detected post-mortem. Three of the 
cases were found dead, in one case the individual fell from a balcony. In three cases 
MDMB-4en-PINACA was the cause of death or contributed to the death; in the remaining 
case the cause of death was trauma from a fall where the contribution from drugs present 
could not be determined.  
ECDC reported that currently they do not have any information on MDMB-4en-PINACA.  
3.1.3. Social problems 
While there is limited data for MDMB-4en-PINACA, the social risks might share some 
similarities with cannabis and other synthetic cannabinoids. 
Of particular note is that synthetic cannabinoids are increasingly used by vulnerable groups, 
such as prisoners and people experiencing homelessness. Reports suggest that this has 
caused new health and social problems as well as exacerbated existing ones for these 
 
15 In addition, France reported two acute intoxications with probable exposure to MDMB-4en-PINACA. These cases are not 
discussed further in this report. 
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groups. For example, in prisons, alongside the adverse health effects, the market in 
synthetic cannabinoids has been linked to an increase in aggression, violence, bullying, and 
debt. In some cases this has caused a serious threat to the overall safety and security of the 
prison environment (Blackman and Bradley, 2017; HMIP, 2015; Ralphs et al., 2017; User 
Voice, 2016). As such, it is a concern given that six Member States reported seizures of 
MDMB-4en-PINACA in prisons and other custodial settings, and, that overall, approximately 
15 % of all the seizures of MDMB-4en-PINACA made by police occurred in these settings. 
3.1.4. Patterns of use 
There is limited information on the patterns of use of MDMB-4en-PINACA. As MDMB-4en-
PINACA is a synthetic cannabinoid, it could be expected that suppliers as well as users who 
are looking for ‘legal’ substitutes for cannabis and replacements for controlled synthetic 
cannabinoids, may be interested in the substance. This may include individuals subject to 
drug testing (such as drivers, prisoners, those in drug treatment, and those subject to 
workplace drug testing), as commonly used drug tests may be unable to detect the 
compounds. 
In addition, reports suggest that in some areas, high risk drug users and other vulnerable 
groups, such as prisoners and people experiencing homelessness, may specifically seek out 
synthetic cannabinoids as they are readily available and have gained a reputation for 
causing profound intoxication while being comparatively cheaper to other drugs. In addition, 
synthetic cannabinoids, particularly when impregnated on to paper, can be easy to smuggle 
into prison and other custodial settings.  
Detections of MDMB-4en-PINACA in prisons and other custodial settings have been 
reported both in the scientific literature (Norman et al., 2020; Yeter et al., 2020) and cases 
reported to the EMCDDA. Six Member States reported seizures of MDMB-4en-PINACA in 
prisons and other custodial settings to the EMCDDA; overall, approximately 15 % of all the 
seizures of MDMB-4en-PINACA made by police occurred in these settings. In addition, 
according to information reported by the United Kingdom, MDMB-4en-PINACA is currently 
the most prevalent synthetic cannabinoid in prisons in Scotland (McKenzie 2020). 
Although limited, there is some information to suggest a recent increase in vaping of 
synthetic cannabinoids using electronic cigarettes by young people, including teenagers, in 
some Member States.  
Similar to other new psychoactive substances, it also appears that there is interest in 
MDMB-4en-PINACA by people who self-experiment with a range of substances (so called 
‘psychonauts’). 
Although MDMB-4en-PINACA may be deliberately sought after by some users, it most 
cases, such as those that purchase it at street-level, they are likely to be unaware that they 
are using the substance which presents an inherent risk to the individuals. 
There are three main types of products containing MDMB-4en-PINACA that are sold on the 
drug market. The most common products are smoking mixtures, where MDMB-4en-PINACA 
is mixed with herbal plant material or tobacco that is then smoked or inhaled from a 
vaporiser (similar to herbal cannabis, the mixture is usually prepared for smoking as a hand-
rolled cigarette (‘joint’)). There are also e-liquids, where a solution of MDMB-4en-PINACA is 
13 
prepared by mixing it with a solvent, which is then vaped using an electronic cigarette 
(Gaulier et al., 2020). In addition, MDMB-4en-PINACA is also impregnated on to paper 
which can then be smoked or vaped. The latter is a commonly used approach to smuggle 
synthetic cannabinoids into prison in some countries. To a lesser extent, users may prepare 
their own similar products using MDMB-4en-PINACA purchased from a vendor or dealer. 
3.2. Chemical and physical description of the new psychoactive substance and the 
methods and precursors used for its manufacture or extraction 
3.2.1. Chemical description and names 
MDMB-4en-PINACA is a synthetic cannabinoid receptor agonist. It contains an indazole 
core, a common structural feature in many of the synthetic cannabinoids monitored by the 
EMCDDA, a carboxamide link, a dimethyl methyl butanoate linked group and a pent-4-ene 
moiety on a pentyl tail. 
MDMB-4en-PINACA appears not to have been described in the scientific or patent literature 
prior to the first identification on the drug market in Europe in 2017. 
MDMB-4en-PINACA shares structural features with a number of substances, including: 5F-
MDMB-PICA (16), 4F-MDMB-BINACA (16), 5F-MDMB-PINACA (17),and 4F-MDMB-BICA (18). 
Structurally, MDMB-4en-PINACA differs in the tail (4-fluorobutyl) from 4F-MDMB-BINACA 
and (5-fluoropentyl) from 5F-MDMB-PINACA; in the core (indole) and tail (5-fluoropentyl) 
from 5F-MDMB-PICA; and in the core (indole) and tail (4-fluorobutyl) from 4F-MDMB-BICA. 
The molecular structure, molecular formula and molecular mass of MDMB-4en-PINACA are 
provided in Figure 1.
 
16 5F-MDMB-PICA and 4F-MDMB-BINACA were critically reviewed by the WHO’s Expert Committee on Drug Dependence 
(ECDD) in 2019 and have been added to Schedule II of the 1971 United Nations Single Convention on Psychotropic 
Substances, which will come into force on 3 November 2020. 
17 5F-MDMB-PINACA was critically reviewed by ECDD in 2017 and is internationally controlled under Schedule II of the 1971 
United Nations Single Convention on Psychotropic Substances. 
18 4F-MDMB-BICA is the subject of an EMCDDA initial report. 
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Figure 1. Molecular structure, molecular formula, and molecular mass of MDMB-4en-
PINACA. Information on 4F-MDMB-BINACA, 5F-MDMB-PINACA, 5F-MDMB-PICA and 4F-
MDMB-BICA is provided for comparison. 
 













C20H27N3O3 C19H26FN3O3 C20H28FN3O3 C21H29FN2O3 C20H27FN2O3 
Molecular 
mass  




Systematic (IUPAC) name: 
Methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido)butanoate 







 MDMB-PINACA N1-pentyl-4-en isomer 
 5Cl-ADB-A (23) 
 
19 Methyl 2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate 
20 Methyl 2-[[1-(5-fluoropentyl)indazole-3-carbonyl]amino]-3,3-dimethyl-butanoate 
21 Methyl 2-[[1-(5-fluoropentyl)indole-3-carbonyl]amino]-3,3-dimethyl-butanoate 
22 Methyl 2-({[1-(4-fluorobutyl)-1H-indol-3-yl]carbonyl}amino)-3,3-dimethylbutanoate 
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 ADB-PINACA-A  
Chemical Abstracts Service (CAS) registry numbers: 
 Not registered 
IUPAC International Chemical Identifier Key (InCHI Key): 
LWOCBHBFWNGPGM-UHFFFAOYSA-N  
Simplified Molecular-Input Line-Entry System (SMILES): 
 COC(=O)C(NC(=O)c1nn(CCCC=C)c2ccccc12)C(C)(C)C 
3.2.2. Physical description 
There is no information available on the solubility, lipophilicity, melting and boiling points or 
other physico-chemical properties of MDMB-4en-PINACA. 
MDMB-4en-PINACA is reported to be soluble in methanol (MeOH) (NPS Discovery, 2019; 
Norman et al., 2020a), deuterated chloroform (CDCl3) (Norman et al., 2020a) and due to its 
similarity to 5F-MDMB-PINACA, MDMB-4en-PINACA is also expected to be soluble in 
ethanol (EtOH), dimethyl sulfoxide (DMSO) and partially soluble in water. 
To date, seizures and collected samples containing MDMB-4en-PINACA, reported to the 
EMCDDA, have been in white, beige, yellow and orange powders and in herbal material. 
MDMB-4en-PINACA has also been identified in blotters, papers impregnated with the 
substance and in liquids contained in vape cartridges. 
MDMB-4en-PINACA has been detected in combination with other synthetic cannabinoids 
including: 5F-MDMB-PICA, 4F-MDMB-BICA, 4F-MDMB-BINACA, 5Cl-AB-PINACA, 5F-
EMB-PICA, AMB-FUBINACA, AB-FUBINACA, Cumyl-PeGaClone, CUMYL-4CN-BINACA, 
Cumyl-5F-PINACA and JWH-210.  
In at least some of the detections, the free base of MDMB-4en-PINACA was identified. 
A more detailed description of seizures and collected samples can be found in section 3.1.1. 
3.2.3. Methods and chemical precursors used for the manufacture or extraction 
No information was reported by the Member States, Norway, or Turkey about the chemical 
precursors or manufacturing methods used to make the MDMB-4en-PINACA which has 
been identified within Europe. 
The synthesis of the S-enantioner of MDMB-4en-PINACA has recently been published in the 
literature (Norman et al., 2020a). The authors reported that MDMB-4en-PINACA, 5F-MDMB-
PINACA and 4F-MDMB-BINACA can be prepared using similar synthetic routes (Norman et. 
al., 2020a). 
 
23 MDMB-4en-PINACA has, in some instances, been incorrectly advertised online as ‘5Cl-ADB-A’. 
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The synthesis of MDMB-4en-PINACA may be carried out in analogy to the synthesis of 5F-
MDMB-PINACA, described by Banister et al., starting with methyl 1H-indazole-3-carboxylate 
which was reacted with methyl L-tert-leucinate, yielding (S)-5F-MDMB-PINACA (Banister et 
al., 2016). The (R)-enantiomer might be synthesised under identical conditions using methyl 
D-tert-leucinate instead of methyl L-tert-leucinate. Using methyl tert-leucinate as a racemate 
would lead to the production of the racemic substance. 
Potential precursors of MDMB-4en-PINACA are methyl 1H-indazole-3-carboxylate, 5-bromo-
1-pentene, and L-tert-leucine methyl ester (for the synthesis of the (S) enantiomer). 
There is no information on the actual manufacturing methods used to make the MDMB-4en-
PINACA which has been identified in Europe. 
3.2.4. Detection and analysis 
Methods documented in the literature for the identification of MDMB-4en-PINACA in physical 
samples include: gas chromatography–mass spectrometry (GC-MS) (NPS Discovery, 2019; 
Cayman Chemical, 2020; RESPONSE, 2018; Norman et al., 2020a); Fourier transform 
infrared spectroscopy (FTIR), high-performance liquid chromatography (HPLC) and 1H, 13C 
and 19F nuclear magnetic resonance spectroscopy (NMR) (RESPONSE 2018); ultra-
performance liquid chromatography-photodiode detector-quadrupole/time of flight-mass 
spectrometry (UPLC-PDA-Q/TOF-MS) and Ion mobility spectrometry (IMS) (Norman et al., 
2020a; Norman et al., 2020b). 
In an analysis of 360 individual seized paper samples from three Scottish prisons between 1 
June 2018 and 27 September 2019, 146 samples (41%) were found to contain at least one 
synthetic cannabinoid. Of these, 22 samples (15%) were found to contain MDMB-4en-
PINACA ranging in concentration from <0.07 ± 0.01 to 0.58 ± 0.09 mg/cm2 paper (Norman et 
al., 2020a).  
Concentration mapping data from two seized paper samples in this study, found to contain 
AMB-CHMICA (24) and 5F-MDMB-PICA, demonstrated that in the case of AMB-CHMICA 
‘concentrations across papers were ‘highly variable (0.47 - 2.38 mg/cm2 paper) making 
consistent dosing by users, and representative sampling by laboratory analysts, difficult’ 
(Norman et al., 2020a).  
The variation in synthetic cannabinoid concentration in these papers has been attributed to 
the method employed for the preparation of synthetic cannabinoid impregnated papers and 
indicates that the synthetic cannabinoid was likely added to the centre of the paper with the 
solution moving outward (Norman et al., 2020a). In a simulated test, the authors 
demonstrated that the distribution of a synthetic cannabinoid across an impregnated paper 
was less variable when the paper was laid flat compared to when hung up to dry, with 
concentrations considerably higher at the bottom of the papers hung up to dry (Norman et 
al., 2020a). 
In the same study, it was noted that between April and May 2019, 73% (16 samples) of all 
MDMB-4en-PINACA detections were also found to contain 4F-MDMB-BINACA as a major 
 
24 methyl 2-[[1-(cyclohexylmethyl)indole-3-carbonyl]amino]-3-methyl-butanoate 
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component. The authors also highlighted the increasing prevalence of MDMB-4en-PINACA 
in detections over the course of their studies from June 2018 to September 2019 and from 
September to 18 December 2019 (Norman et al., 2020a; Norman et al., 2020b). 
MDMB-4en-PINACA was identified in a ratio ‘per plant material of 1.56% to 2.09% w/w’ in a 
seizure of three ‘Spice’ samples, in July 2020, in the UK. In the report submitted by the UK, it 
was noted that this was between 1.5 to 2 times the ratio of MDMB-4en-PINACA found in 
seized samples tested in June 2020. 
Quantification of MDMB-4en-PINACA in products can be carried out according to the 
general procedure described by the UNODC (UNODC, 2013). 
Methods documented in the literature for the identification of MDMB-4en-PINACA in 
biological samples include: liquid chromatography-quadrupole time of flight-mass 
spectrometry (LC-QTOF-MS) (NPS Discovery, 2019; Krotulski et al., 2020); liquid 
chromatography–high-resolution mass spectrometry (LC–HRMS) (Yeter et al., 2020); and 
liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) 
(Watanabe et al., 2020). 
Krotulski et al. noted the importance of the detection of MDMB-4en-PINACA 3,3-
dimethylbutanoic acid in blood samples, highlighting that the detection of butanoic acid 
metabolites was ‘as the result of instability of parent synthetic cannabinoids, especially with 
methyl ester species’ (Krotulski et al., 2020). The authors indicated that MDMB-4en-PINACA 
may be susceptible to matrix instability and as a result suggested that MDMB-4en-PINACA 
3,3-dimethylbutanoic acid may be an ‘equally appropriate target when testing blood samples 
for synthetic cannabinoids, even after just short periods of time when blood samples are 
refrigerated’ (Krotulski et al., 2020). The authors recommended that cases be interpreted as 
MDMB-4en-PINACA ingestion if a blood sample is positive for MDMB-4en-PINACA 3,3-
dimethylbutanoic acid but negative for MDMB-4en-PINACA, once other similar alkylated 
analogues have not been detected on the drugs market and while also taking note of the 
case history and post-mortem findings (Krotulski et al., 2020). 
Krotulski et al. additionally flagged the potential requirement in toxicology testing for 
emerging synthetic cannabinoids for ‘high sensitivity platforms (e.g., LC-MS/MS) due to 
increased potency over compounds from previous generations and corresponding lower 
concentrations’ (Krotulski et al., 2020). 
MDMB-4en-PINACA contains a stereocentre thus allowing for the existence of a pair of 
enantiomers, (R)- and (S)-MDMB-4en-PINACA. The S-enantiomer of MDMB-4en-PINACA is 
available as a reference standard, in the form of a neat solid (25). Methods documented in 
the literature for the characterisation of (S)-MDMB-4en-PINACA include: GC-MS (Cayman 
Chemical, 2020; Normal et al., 2020a) and NMR spectroscopy (Normal et al.,2020a). 
There is no representative information on the enantiomeric composition of the samples of 
MDMB-4en-PINACA detected within the European Union, which in part may reflect the fact 
that stereochemical analysis is not routinely undertaken in forensic laboratories. Based on 
 
25 https://www.caymanchem.com/product/26097/mdmb-4en-pinaca  
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the literature of similar compounds (Banister et al., 2016) and the most likely precursors to 
be used, an (S)-configuration of the stereocentre could be expected. 
Differentiation of enantiomers is possible using the following techniques: chiral 
chromatography, vibrational circular dichroism (VCD) spectroscopy and/or electronic circular 
dichroism (ECD) spectroscopy. 
MDMB-4en-PINACA and MBA-CHMINACA (26), also known as AB-CHMINACA metabolite 
M2, are isomers therefore it is important to note that GC-MS analysis of these substances 
will result in very similar mass spectrometry fragmentation patterns. The ability to distinguish 
between isomers requires the use of analytical reference standards, access to reference 
spectra for both substances, and/or additional analytical methods (27). 
MDMB-4en-PINACA is currently screened for in some, but not all, forensic and toxicology 
laboratories in Europe. As a result, some cases of MDMB-4en-PINACA are likely to be 
undetected and under reported, leading to incomplete data regarding detections of MDMB-
4en-PINACA in Europe. 
3.3. Pharmacological and toxicological description of the new psychoactive 
substance 
MDMB-4en-PINACA is a synthetic cannabinoid receptor agonist. Limited data suggests that 
MDMB-4en-PINACA is a CB1 receptor agonist (Antonides et al., 2020; ECDD 2020; Krotulski 
et al., 2020; NBFM and PHA, 2019) that shares some similarities with the major 
psychoactive constituent of cannabis Δ9-tetrahydrocannabinol (THC) and other synthetic 
cannabinoids. 
The acute effects of THC (and consequently cannabis) include: relaxation, euphoria, 
lethargy, depersonalisation, distorted perception of time, impaired motor performance, 
hallucinations, paranoia, confusion, fear, anxiety, dry mouth, reddening of the conjunctivae 
of the eyes, tachycardia, and, nausea and vomiting. THC also has an abuse liability and 
dependence potential (Pertwee, 2014; Wiley et al., 2016). Similar effects to cannabis have 
been reported for synthetic cannabinoids such as MDMB-4en-PINACA. In some cases, the 
effects are reported to be more pronounced/severe (EMCDDA, 2017).  
Compared to cannabis, severe and fatal poisoning appears to be more common with 
synthetic cannabinoids (EMCDDA, 2017; Tait et al., 2016). Poisoning may include rapid loss 
of consciousness/coma, cardiovascular effects (such as hypertension, tachycardia, 
bradycardia, chest pain, myocardial infarction, and stroke), seizures and convulsions, 
vomiting/hyperemesis, delirium, agitation, psychosis, and, aggressive and violent behaviour. 
Sudden death has also been reported. The mechanisms of this toxicity are poorly 
understood (Tai and Fantegrossi, 2016), but factors that are likely to play an important role 
are the potency of the substances and the doses that users are exposed to. In addition, 
some of the effects of poisoning — such as loss of consciousness or behavioural effects — 
may place users at additional risks such as choking on vomitus, drowning, or self-harm. 
 
26 2-[[1-(Cyclohexylmethyl)indazole-3-carbonyl]amino]-3-methyl-butanoic acid 
27 https://www.caymanchem.com/product/16389/ab-chminaca-metabolite-m2  
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Currently there is no antidote to poisoning caused by synthetic cannabinoids. 
In general, the use of smoking mixtures containing synthetic cannabinoids appears to pose a 
high risk of poisoning. This is because manufacturers guess the amount of cannabinoids(s) 
to add to the herbal material, and the manufacturing process makes it difficult to dilute them 
sufficiently and distribute them consistently throughout the material. This can result in 
mixtures that contain a large amount of highly potent cannabinoid, as well as ‘hot pockets’ 
where the cannabinoid is highly concentrated within parts of the herbal material (Schäper, 
2016). Together, this makes it difficult for users to control the dose that they are exposed to. 
As these mixtures are typically smoked as cigarettes ('joints'), users can inadvertently 
administer a toxic dose; in some cases, a small number of puffs from a cigarette have been 
sufficient to cause severe poisoning. Reflecting these risks, smoking mixtures have caused 
a large number of outbreaks of mass poisonings in recent years (Adams et al., 2017; Kasper 
et al., 2015; Schwartz et al., 2015; Shevyrin et al., 2015; Trecki et al., 2015; Tyndall et al., 
2015). Such outbreaks have the potential to overwhelm local healthcare systems, which is of 
particular concern considering the ongoing COVID-19 pandemic. 
While there is limited data for MDMB-4en-PINACA, the chronic health risks might share 
similarities to cannabis and other synthetic cannabinoids. This may include dependence. 
ECHA reported to the EMCDDA that they do not currently have any information on MDMB-
4en-PINACA at their disposal, in particular any data on its toxicological properties. EFSA 
reported to the EMCDDA that they do not currently have any information on MDMB-4en-
PINACA, including both describing the hazard and concerning human exposure. 
3.4. Involvement of criminal groups in the manufacture or distribution of the new 
psychoactive substance 
Europol received replies from 19 Member States: Belgium, Bulgaria, Cyprus, Czechia, 
Denmark, Estonia, Finland, France, Germany, Greece, Latvia, Lithuania, Luxembourg, 
Romania, Portugal, Slovakia, Slovenia, Spain and the United Kingdom. 
Replies were also received from the United States (US) Drug Enforcement Administration 
(DEA) (28) and New Zealand (29). 
No information was received on the involvement of criminal groups in the manufacture or 
distribution of MDMB-4en-PINACA. 
Belgium reported 11 seizures of MDMB-4en-PINACA by customs at Liege airport. One 
shipment contained two separate quantities of 16 kilograms of MDMB-4en-PINACA. Belgium 
remarked that they are a transit country for MDMB-4en-PINACA from China to other EU 
Member States, such as Hungary, the Netherlands, Romania and the United Kingdom.  
 
28 The U.S. DEA reported seizures of MDMB-4en-PINACA in 2020. The substance was mixed with fentanyl, heroin, tramadol 
and cocaine. The substance was seized in powder, plant and tablet form. 
29 New Zealand reported a seizure of 500 grams of MDMB-4en-PINACA, by customs, on 9 June 2020. The substance was 
identified in air cargo which was en-route from China and it was also reported that it is likely that the MDMB-4en-PINACA was 
produced there. New Zealand indicated that the amount of MDMB-4en-PINACA seized could be used to prepare at least one 
million doses and it was noted that MDMB-4en-PINACA is incorrectly known as 5-CL-ADB-A and has been described as both a 
white and yellow-brown powder (internationally).  
20 
Bulgaria reported that MDMB-4en-PINACA was identified in 1 gram seized by customs in 
2020. The substance was detected in a courier parcel. 
France reported a few seizures of MDMB-4en-PINACA by customs in recent months. 
MDMB-4en-PINACA was identified in 1.008 kilograms of beige powder seized by customs at 
Roissy Airport, on 8 August 2020. The substance was contained in a heat-sealed bag, 
labelled as ‘polypropylene pigment12 (Yellow), HS 3213100000’, which was en-route via 
express freight, from China to Hungary. MDMB-4en-PINACA was also identified in five 
seizures at St Denis Airport, in Reunion since June 2020. The five seizures amounted to a 
total of 2.073 grams which were en-route, via express freight, from China to Reunion. 
France also highlighted that MDMB-4en-PINACA has in recent months been identified in ‘La 
Chimique’, a term given to plant/herbal material which had been mostly found to contain the 
synthetic cannabinoids AB-CHIMINACA, AB-FUBINACA. They reported that following the 
national lockdown in France, as a result of Covid-19, seizures of ‘La Chimique’ were 
subsequently found to contain the synthetic cannabinoids MDMB-4en-PINACA, 4F-MDMB-
BINACA and 5F-MDMB-PICA. ‘La Chimique’ is reportedly ordered online and delivered by 
post from China and is considered to be popular amongst young people (18 and 25 years 
old) in both the Mayotte and Reunion region of France. 
Latvia reported that MDMB-4en-PINACA was identified in 7 seizures in the first 6 months of 
2020. Whilst no information was available on the origin of the substance, they noted that 
detections occurred within one district, suggesting a single distributor of MDMB-4en-PINACA 
in that region. 
Portugal did not report any seizures of MDMB-4en-PINACA by police however they reported 
a case of MDMB-4en-PINACA, from 4 January 2020, associated with hospital admissions of 
some individuals. 
Romania reported that MDMB-4en-PINACA has been identified since between April and 
May 2020, in plant/herbal material or powder form. 
Slovakia reported that MDMB-4en-PINACA was identified with 4F-MDMB-BICA and A-
CHMINACA (30) in yellow crystalline material, contained in 2 plastic tubes, seized in postal 
consignments en-route from the Netherlands to Hong Kong, in September 2020. 
Slovenia reported two seizures of 3.34 grams and 0.3 grams of MDMB-4en-PINACA in plant 
material, which occurred in a prison, on 25 August 2020.  
In addition, the US DEA reported seizures of MDMB-4en-PINACA in 2020. The substance 
was mixed with fentanyl, heroin, tramadol and cocaine. The substance was seized in 
powder, plant and tablet form. 
New Zealand reported a seizure of 500 grams of MDMB-4en-PINACA, by customs, on 9 
June 2020. The substance was identified in air cargo which was en-route from China and it 
was also reported that it is likely that the MDMB-4en-PINACA was produced there. New 




at least one million doses and it was noted that MDMB-4en-PINACA is incorrectly known as 
5-CL-ADB-A and has been described as both a white and yellow-brown powder. 
3.5. Information on the human and veterinary medical use of the new psychoactive 
substance, including as an active substance in a medicinal product for human 
use or in a veterinary medicinal product 
Based on the reported information from the EMA (31), it appears that MDMB-4en-PINACA is 
not an active substance in: 
a. a medicinal product for human use or in a veterinary medicinal product that has 
obtained a marketing authorisation in accordance with Directive 2001/83/ EC of the 
European Parliament and of the Council, Directive 2001/82/EC of the European 
Parliament and of the Council or Regulation (EC) No 726/2004 of the European 
Parliament and of the Council;  
b. a medicinal product for human use or in a veterinary medicinal product that is the 
subject of an application for a marketing authorisation;  
c. a medicinal product for human use or in a veterinary medicinal product whose 
marketing authorisation has been suspended by the competent authority. 
In addition, it appears that MDMB-4en-PINACA is not an active substance in the following, 
although the information, especially in relation to use in extemporaneously prepared 
products, is unknown in some cases: 
d. an unauthorised medicinal product for human use in accordance with Article 5 of 
Directive 2001/83/ EC or in a veterinary medicinal product prepared 
extemporaneously by a person authorised to do so under national law in 
accordance with point (c) of Article 10(1) of Directive 2001/82/EC;  
e. an investigational medicinal product as defined in point (d) of Article 2 of Directive 
2001/20/EC of the European Parliament and of the Council. 
3.6. Information on the commercial and industrial use of the new psychoactive 
substance, the extent of such use, as well as its use for scientific research and 
development purposes 
MDMB-4en-PINACA is used as an analytical reference material in clinical and forensic case 
work as well as scientific research. There is currently no information that suggests MDMB-
4en-PINACA is used for other legitimate purposes.  
ECHA and EFSA reported that MDMB-4en-PINACA did not retrieve any results in their 
databases.  
 
31 26 Member States, as well as Norway and Iceland provided a response to the EMA’s request regarding human and/or 
veterinary medicinal products.  
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3.7. Information on whether the new psychoactive substance is subject to any 
restrictive measures in the Member States 
Fourteen Member States (Bulgaria, Czechia, Denmark, Estonia, Greece, Ireland, Italy, 
Malta, the Netherlands, Portugal, Romania, Slovakia, Slovenia, and Spain) reported that 
MDMB-4en-PINACA is not subject to restrictive measures at national level.  
Drug control legislation 
Nine Member States (Croatia, Cyprus, Finland, France, Latvia, Luxembourg, Poland, 
Sweden, and the United Kingdom) and Turkey reported that MDMB-4en-PINACA is 
controlled under drug control legislation. 
• Croatia reported that MDMB-4en-PINACA is controlled within the List of drugs, 
psychotropic substances and plants used to produce drugs, and substances that can 
be used for the production of drugs (OG 13/19) since 2016. 
• Cyprus reported that MDMB-4en-PINACA is controlled under drug control legislation 
(generic legislation) since 15 June 2018. 
• Finland reported that MDMB-4en-PINACA is covered by the Government degree on 
psychoactive substances banned from the consumer market (1130/2014) since 15 
August 2019. 
• France reported that MDMB-4en-PINACA is controlled under drug control legislation 
(NOR: AFSP1710288A) since 31 March 2017. 
• Latvia reported that MDMB-4en-PINACA is controlled under drug control legislation 
(the Law on Procedures for the Coming into force and Application of the Criminal 
Law) since 2013.  
• Luxembourg reported that MDMB-4en-PINACA is controlled under drug control 
legislation (RGD du 20 avril 2009 modifiant le RGD modifié du 20 mars 1974 
concernant certaines substances psychotropes) since 2009.  
• Poland reported that MDMB-4en-PINACA is covered by generic definition of 
synthetic cannabinoids (Regulation of the Minister of Health on Regulation of the 
Minister of Health on list of psychotropic drugs, psychoactive substances and new 
psychoactive substances; main act: Act on Counteracting Drug Addiction) since July 
2018. 
• Sweden reported that MDMB-4en-PINACA is regulated as a narcotic since 11 
February 2020. 
• United Kingdom reported that MDMB-4en-PINACA is controlled under the Misuse of 
Drugs Act 1971 since 02 December 2016. 
• Turkey reported that MDMB-4en-PINACA is included in Law on Drug Control No. 
2313 (taken automatically under legal control with the generic legislation as the NPS 
detected in the country) as of March 2019. 
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New psychoactive substance legislation 
Four Member States (Austria, Belgium, Germany, and Hungary) reported that MDMB-4en-
PINACA is controlled under specific new psychoactive substances control legislation. 
• Austria reported that MDMB-4en-PINACA is covered by the Austrian Act on New 
Psychoactive Substances.  
• Belgium reported that MDMB-4en-PINACA is controlled under Belgian Generic 
Legislation, active since September 2017.  
• Germany reported that MDMB-4en-PINACA is covered by the New Psychoactive 
Substances Act (NpSG).  
• Hungary reported that MDMB-4en-PINACA is controlled under specific NPS control 
legislation (Regulation 55/2014 (XII.30) of the Ministry of Human Capacities). 
Medicines legislation 
Lithuania and Norway reported that MDMB-4en-PINACA is controlled under medicines 
legislation. 
• Lithuania reported that MDMB-4en-PINACA is controlled under medicines legislation 
(falls under the definition of the generic group of synthetic cannabinoids) since 21 
September 2015.  
• Norway reported that MDMB-4en-PINACA is controlled under the Norwegian Law of 
Medicines. 
3.8. Information on whether the new psychoactive substance is currently or has 
been under assessment within the system established by the 1961 Single 
Convention on Narcotic Drugs, as amended by the 1972 Protocol, and the 1971 
Convention on Psychotropic Substances  
The World Health Organization is the specialised United Nations agency designated for the 
evaluation of the medical, scientific, and public health aspects of psychoactive substances 
under the Single Convention on Narcotic Drugs, 1961, and the Convention on Psychotropic 
Substances, 1971. 
On 1 October 2020, the WHO informed the EMCDDA that MDMB-4en-PINACA will be 
assessed at the 43rd meeting of the WHO Expert Committee on Drug Dependence (ECDD) 
that will be held on 12–16 October 2020. At the time of writing this report a critical review 
had been published, however, a written recommendation had not been published. 
During the data collection process, significant new data have been reported to the EMCDDA 
to suggest the need for a risk assessment at Union level. In particular, information on recent 
large scale seizures and health harms associated with MDMB-4en-PINACA indicate that 
MDMB-4en-PINACA might pose health and social threat at Union level. 
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3.9. Other relevant information 
United Kingdom 
In the United Kingdom, 84 samples containing MDMB-4en-PINACA were submitted to 
WEDINOS (32) between August 2019 and September 2020. Of these, 76 samples (90%) 
were submitted in 2020. 57 (68%) of the samples submitted to WEDINOS were herbal 
material. The self-reported effects from users were consistent with synthetic cannabinoids, 
and included euphoria, relaxation, chest pains, irregular heartbeat, vomiting, confusion, 
agitation, auditory and visual hallucinations, and paranoia (WEDINOS, 2020). 
Switzerland 
In Switzerland, the drug checking service Saferparty reported 37 samples of cannabis 
adulterated with MDMB-4en-PINACA between May and September 2020. Nineteen samples 
contained other synthetic cannabinoids such as 5F-MDMB-PICA, 4F-MDMB-BINACA, 5F-
ADBICA-A, 4F-MDMB-BICA and THJ-018 (Saferparty, 2020). 
United States 
In the United States, the Centre for Forensic Science Research and Education (CFSRE) 
reported the first identification of MDMB-4en-PINACA in July 2019. The report was related to 
two biological samples from post-mortem investigations from 2019. In one case the synthetic 
cannabinoid 5F-MDMB-PICA was also identified (NPS Discovery, 2019).  
MDMB-4en-PINACA has been identified in 25 forensic toxicology cases in the United States. 
The majority of cases (n = 16, 64%) were submitted from postmortem investigations, 
followed by eight cases from suspected clinical toxicology investigations, and one case from 
an impaired driving investigation. The samples were collected between May 2019 and March 
2020 and were from many regions across the United States. In seven cases, MDMB-4en-
PINACA was the only drug reported, excluding incidental findings (e.g., caffeine and 
nicotine). Based on information from the death investigations, two death cases happened in 
prison settings and one case involved homeless individual. Authors reported that results 
from toxicology testing paired with case history show the potential for MDMB-4en-PINACA to 
cause or contribute to impairment or death (Krotulski et al., 2020). 
4. Analysis and assessment  
Methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido)butanoate (MDMB-
4en-PINACA) is a synthetic cannabinoid receptor agonist monitored by the EMCDDA as a 
new psychoactive substance in accordance with Regulation (EC) No 1920/2006 (as 
amended).  
MDMB-4en-PINACA has been available on the drug market in Europe since at least 2017. 
The substance is sold as a ‘legal’ replacement for cannabis and other controlled synthetic 
cannabinoids. Limited information suggests that MDMB-4en-PINACA is a potent CB1 
 
32 WEDINOS is a drug testing service in the United Kingdom operated by Public Health Wales. 
http://www.wedinos.org/about_us.html  
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receptor agonist, and, as such, shares some pharmacological similarities with Δ9-
tetrahydrocannabinol (THC), which is responsible for the major psychoactive effects of 
cannabis, and other synthetic cannabinoids, such as JWH-018, which are under 
international control. 
The available information suggests that MDMB-4en-PINACA is manufactured by chemical 
companies based in China. It is imported into Europe as bulk powders and then sold and 
distributed in wholesale and retail amounts within Europe either as a powder for processing 
into products or finished consumers products. There are three main types of products 
containing MDMB-4en-PINACA that are sold on the drug market: smoking mixtures, where 
MDMB-4en-PINACA is mixed with herbal plant material or tobacco that is then smoked or 
inhaled from a vaporiser (similar to herbal cannabis, the mixture is usually prepared for 
smoking as a hand-rolled cigarette (‘joint’)); e-liquids, where a solution of MDMB-4en-
PINACA is prepared by mixing it with a solvent, which is then vaped using an electronic 
cigarette; in addition, MDMB-4en-PINACA is also impregnated on to paper which can then 
be smoked or vaped. The latter is a commonly used approach to smuggle synthetic 
cannabinoids into prison in some countries. To a lesser extent, users may prepare their own 
similar products using MDMB-4en-PINACA purchased from a vendor or dealer. 
As of October 2020, MDMB-4en-PINACA has been identified in twenty Member States as 
well as Turkey and Norway; 768 seizures have been reported, which includes approximately 
47 kg of powder and 4.7 kg of smoking mixtures. Although MDMB-4en-PINACA was first 
identified on the drug market in 2017, it is only since 2019 that there has been a large 
increase in the number of Member States identifying the substance for the first time. In 
addition, during 2020 there was a large increase in the quantity of MDMB-4en-PINACA 
seized by customs, with approximately 94% of the total amount of powder (44 kg) seized by 
customs during the year. 
A total of eleven acute non-fatal poisonings with confirmed exposure to MDMB-4en-PINACA 
have been reported by one Member State, the United Kingdom. The cases occurred 
between January and August 2020. While exposure to other substances was reported in 
most cases, including other synthetic cannabinoids, at least some of the clinical features of 
the poisonings were consistent with exposure to synthetic cannabinoids. In ten of the cases, 
the poisoning was reported to be life-threatening and required hospitalisation of the patient. 
A total of four deaths with confirmed exposure to MDMB-4en-PINACA have been reported 
by two Member States, Sweden and the United Kingdom. The deaths occurred between 
January 2019 and June 2020. In three cases, MDMB-4en-PINACA was reported to be the 
cause of death or to have contributed to the death. 
It is important to note that the presence of MDMB-4en-PINACA on the drug market and in 
serious adverse events may be undetected in Europe since the substance is not routinely 
screened for in some laboratories. 
The available data suggests that MDMB-4en-PINACA may be used by cannabis users, by 
those who are regularly subjected to drug testing procedures (including those in prison), and 
by people who self-experiment with a range of psychoactive substances (so-called 
‘psychonauts’). MDMB-4en-PINACA may also be used by high risk drug users and other 
marginalised groups, such as people experiencing homelessness and prisoners, as 
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synthetic cannabinoids are typically readily available, and have gained a reputation for 
causing profound intoxication while being comparatively cheaper to other drugs. In addition, 
synthetic cannabinoids can be easy to smuggle into the prison environment. Although 
limited, there is some information to suggest a recent increase in vaping of synthetic 
cannabinoids using electronic cigarettes, including MDMB-4en-PINACA, by young people, 
including teenagers, in some Member States.  
Because of their high potency and the unintentionally high doses that users may be exposed 
to, synthetic cannabinoids can pose a high risk of severe poisoning, which in some cases 
can be fatal. These factors can also be responsible for the outbreaks of mass poisonings 
seen with synthetic cannabinoids. Such outbreaks have the potential to overwhelm local 
healthcare systems, which is of particular concern given the ongoing COVID-19 pandemic 
and the additional burden already on healthcare systems. There is no approved antidote to 
poisoning caused by synthetic cannabinoids. 
In prisons, alongside the adverse health effects, the market in synthetic cannabinoids has 
been linked to an increase in aggression, violence, bullying, and debt. In some cases this 
has caused a serious threat to the overall safety and security of the prison environment. As 
such, it is a concern given that six Member States reported seizures of MDMB-4en-PINACA 
in prisons and other custodial settings, and, that overall, approximately 15 % of all the 
seizures of MDMB-4en-PINACA made by police occurred in these settings. 
There is no information whether or not criminal groups are involved in the manufacture, 
trafficking, and distribution of MDMB-4en-PINACA within Europe. However, based on 
information reported to the EMCDDA, there is evidence of criminal acts, such as supply 
offences, involving MDMB-4en-PINACA. 
The effect of the ongoing COVID-19 pandemic on the manufacture, trafficking, distribution, 
and use of MDMB-4en-PINACA is currently unknown. However, seizures of more than 44 kg 
of bulk powders by a European national customs agency during the pandemic suggests that 
attempts at large-scale importation into and distribution within Europe are continuing. It is 
also possible, that in case of a reduced availability of cannabis and other synthetic 
cannabinoids in Europe, criminal groups, as well as drug users, may use a range of 
replacement substances, including MDMB-4en-PINACA. 
Based on the available information, it appears that MDMB-4en-PINACA is not an active 
substance in a medicinal product for human use or in a veterinary medicinal product in 
Europe. However, the use of MDMB-4en-PINACA as an active substance in medicinal 
products prepared extemporaneously or in investigational medicinal products cannot be 
excluded in some Member States due to a lack of information. Aside from limited use as an 
analytical reference standard and in scientific research, there is currently no information that 
suggests MDMB-4en-PINACA is used for other legitimate purposes. 
MDMB-4en-PINACA is subject to restrictive measures in fourteen Member States, Turkey, 
and Norway. It is unknown if MDMB-4en-PINACA is controlled in China, where at least some 
of the substance on the European market has been sourced from.  
MDMB-4en-PINACA is under assessment within the United Nations system. It will be 
assessed at the 43rd meeting of the WHO Expert Committee on Drug Dependence (ECDD) 
that will be held in October 2020. At the time of writing this initial report, a critical review had 
27 
been published, however, a written recommendation had not. During the initial report 
process, significant new information was reported by the Member States to the EMCDDA 
that provides further evidence that MDMB-4en-PINACA might pose health and social threats 
at Union level. This includes seizures of large quantities of bulk powder of MDMB-4en-
PINACA made in the last few months and recent cases of severe poisonings and deaths 
involving the substance in Europe. 
Based on the information reported to the EMCDDA, there are indications that MDMB-4en-
PINACA has the potential to continue to rapidly spread in Europe. Of note is that, similar to 
4F-MDMB-BICA, which is also currently the subject of an initial report, the recent increase in 
seizures of consignments of bulk powder of MDMB-4en-PINACA made by European 
customs agencies appears to coincide with the recent decision to internationally control two 
closely related synthetic cannabinoids commonly found on the drug market in Europe, 4F-
MDMB-BINACA and 5F-MDMB-PICA. As such, it is possible that MDMB-4en-PINACA will 
be a replacement for these substances. 
The EMCDDA will continue to intensively monitor MDMB-4en-PINACA in order to ensure 
that new information is provided to the Member States, Europol, the Commission, and the 
EMA through the European Union Early Warning System in a timely manner in order to 
strengthen situational awareness as well as to continue to inform preparedness and 
response measures at both national and EU level in order to protect public health. 
Based on the analysis of the available information, the EMCDDA considers that there are 
indications that MDMB-4en-PINACA may pose health or social risks at Union level. We 
conclude that the potential health and social risks posed by the use, manufacture, 
distribution and the involvement of criminal groups, could be thoroughly assessed through a 
risk assessment procedure in accordance with Article 5c of Regulation (EC) No 1920/2006 
(as amended). 
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